UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 ...

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update VANCOUVER, BC and BOSTON, MA, May 12, 2025 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience- focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "We continue to make steady progress across our Phase 3 epilepsy program, with pati ...

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in ...

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information:  Date:Monday, May 12, 2025  Time:4:30 p ...

Xenon Pharmaceuticals (XENE) closed the last trading session at $38.28, gaining 30.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $56.71 indicates a 48.2% upside potential.The average comprises 14 short-term price targets ranging from a low of $42 to a high of $65, with a standard deviation of $6.73. While the lowest estimate indicates an increase of 9.7% from the current price ...

文章核心观点 公司宣布向四名新非管理人员授予股权奖励，包括78,600份股票期权和1,800份绩效股票单位 [1] 股权奖励授予情况 - 授予对象为四名新非管理人员 [1] - 授予内容包括78,600份股票期权和1,800份绩效股票单位 [1] - 授予经公司董事会薪酬委员会批准，生效日期为2025年5月2日，依据纳斯达克上市规则5635(c)(4)作为员工入职诱因授予 [1] 股票期权情况 - 行使价格为每股38.28美元，与2025年5月2日授予日公司普通股收盘价相同 [2] - 分四年归属，员工入职一周年时归属25%，之后每月最后一天归属剩余期权的1/36，需员工持续为公司服务 [2] - 每份期权有效期10年，受股票期权协议和公司2025年诱因股权奖励计划条款约束 [2] 绩效股票单位情况 - 基于约三年绩效期内达成预定里程碑目标归属（若有），需员工持续为公司服务 [2] - 每份授予受绩效股票单位奖励协议和公司2025年诱因股权奖励计划条款约束 [2] 公司简介 - 是专注神经科学的生物制药公司，致力于发现、开发和提供改变生活的疗法 [3] - 推进离子通道产品组合，以满足癫痫和抑郁症等未满足的医疗需求 [3] - 新型、高效、选择性Kv7钾通道开放剂Azetukalner是针对多种适应症处于后期临床开发的最先进、经临床验证的钾通道调节剂 [3] 联系方式 - 投资者联系：副总裁Chad Fugere，电话(857) 675-7275，邮箱investors@xenon-pharma.com [5] - 媒体联系：高级副总裁Colleen Alabiso，电话(617) 671-9238，邮箱media@xenon-pharma.com [5]

Analyst’s Disclosure: I/we have a beneficial long position in the shares of XENE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is not a recommendation to buy or sell any security. I am not a financial advisor. Facts contained within should not be relied up ...

I covered Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) in August. Then, I noted that lead asset azetukalner (XEN1101) was running phase 3 clinical trials targeting two forms of epilepsy, focal onset seizure (FOS’) and Primary Generalized Tonic-Clonic Seizures (PGTCS), and a phase 3 trial called X-NOVA2About the TPT ServiceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where yo ...

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical co ...

文章核心观点 - 2024年第四季度和全年赛诺制药亏损收窄 公司无上市产品 主要依赖合作收入 多个在研项目有进展 目前现金余额可支持运营至2027年 公司当前评级为持有 同时推荐了其他排名较好的股票 [1][8][7][17] 第四季度业绩详情 - 2024年第四季度每股亏损84美分 小于扎克斯普遍预期的89美分 上年同期每股亏损64美分 [1] - 本季度无营收 因无上市产品 仅从与Neurocrine Biosciences的合作中获得周期性合作收入 上年同期也无营收 [2] - 研发费用同比增长45%至5950万美元 主要因癫痫研究和抑郁症研究费用增加 [5] - 一般及行政费用同比增长43%至1800万美元 因人员成本 股票薪酬和专业咨询费用增加 [6] - 截至2024年12月31日 现金 现金等价物和有价证券为7.544亿美元 低于9月30日的8.033亿美元 现有现金余额预计可支持当前运营计划至2027年 [7] - 过去三个月 公司股价下跌10.1% 行业下跌2% [5] 全年业绩情况 - 2024年无营收 每股亏损3.01美元 小于扎克斯普遍预期的3.10美元 2023年每股亏损2.73美元 [8] 产品线更新 - 公司暂无获批产品 重点在管线开发 [9] - 阿泽图卡尔纳用于治疗局灶性发作癫痫的III期研究中 X - TOLE2和X - TOLE3正在评估15mg或25mg剂量 预计X - TOLE2研究的首批顶线数据将于2025年下半年公布 [10] - 阿泽图卡尔纳用于治疗原发性全面性强直 - 阵挛发作的III期X - ACKT研究正在招募患者 旨在支持该适应症的潜在监管申报 [12] - 阿泽图卡尔纳用于治疗重度抑郁症的II期概念验证研究X - NOVA已完成 基于此 本季度启动了三项III期研究中的第一项X - NOVA2 预计X - NOVA3将于2025年年中左右启动 [13] - 公司宣布了双相抑郁症晚期项目计划 两项临床研究中的第一项将于年中开始 该计划有科学依据 旨在满足未满足的医疗需求 [14] - 公司与西奈山伊坎医学院合作的阿泽图卡尔纳治疗重度抑郁症的II期概念验证研究已完成患者招募 预计2025年上半年公布顶线结果 [15] - 公司正在评估多个针对Kv7、Nav1.7和Nav1.1的临床前治疗候选药物 目标是在2025年推进至临床开发 [16] 合作项目进展 - NBI - 921352是选择性Nav1.6钠通道抑制剂 Neurocrine正在进行II期研究 用于治疗2 - 21岁SCN8A发育性和癫痫性脑病患者 公司可获得里程碑付款和销售特许权使用费 [3] - NBI - 921355是Nav1.2/1.6抑制剂 已进入健康成人I期临床研究 公司获得750万美元里程碑付款 [4] 扎克斯评级及相关股票 - 赛诺制药目前扎克斯评级为3（持有） [17] - 吉利德科学和BioMarin Pharmaceutical评级为2（买入） [17] - 过去30天 吉利德科学2025年和2026年每股收益预期均有提高 过去三个月股价上涨21% 过去四个季度盈利均超预期 平均惊喜率19.47% [18] - 过去30天 BioMarin Pharmaceutical 2025年每股收益预期提高 2026年略有下降 过去三个月股价上涨4.7% 过去四个季度盈利均超预期 平均惊喜率32.36% [19]